-
1Academic Journal
Authors: I. V. Reshetov, V. A. Manukovsky, A. E. Demko, V. V. Cheremisov, A. V. Osipov, S. Sh. Taniya, M. A. Privalov, A. I. Babich, И. В. Решетов, В. А. Мануковский, А. Е. Демко, В. В. Черемисов, А. В. Осипов, С. Ш. Тания, М. А. Привалов, А. И. Бабич
Source: Siberian journal of oncology; Том 23, № 2 (2024); 126-132 ; Сибирский онкологический журнал; Том 23, № 2 (2024); 126-132 ; 2312-3168 ; 1814-4861
Subject Terms: лейомиосаркома, metastatic liver tumors, leiomyosarcoma, метастатическое поражение печени
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/3048/1226; Поликарпов А.А., Таразов П.Г., Гранов Д.А., Полысалов В.Н. Рентгенэндоваскулярные процедуры в лечении больных с нерезектабельными метастазами колоректального рака в печени. Российский онкологический журнал. 2014; 19(4): 40–1.; Таразов П.Г., Поликарпов А.А., Гранов Д.А. Артериальная химиоэмболизация в лечении больных метастазами злокачественного карциноида в печень. Анналы хирургической гепатологии. 2010; 15(3): 19–24.; Adam R., Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3(1): 50–6. doi:10.1002/ags3.12227.; Tzeng C., Aloia T. Colorectal Liver Metastases. J Gastrointest Surg. 2012; 17: 195–201. doi:10.1007/s11605-012-2022-3.; Gruber-Rouh T., Naguib N., Eichler K., Ackermann H., Zangos S., Trojan J., Beeres M., Harth M., Schulz B., Nour-Eldin A., Vogl T.J. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int. J Cancer. 2013; 134: 1225–31. doi:10.1002/ijc.28443.; Alexander H.R., Bartlett D.L., Libutti S.K., Pingpank J.F., Fraker D.L., Royal R., Steinberg S.M., Helsabeck C.B., Beresneva T.H. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center.Ann Surg Oncol. 2009; 16(7): 1852–9. doi:10.1245/s10434-009-0482-9.; Ben-Shabat I., Hansson C.,Eilard M., Cahlin C., Rizell M., Lindnér P., Mattsson J., Bagge R. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp. 2015; (95): 52490. doi:10.3791/52490.; van Iersel L.B.J., Koopman M., van de Velde C.J.H., Mol L., van Persijn van Meerten E.L., Hartgrink H.H., Kuppen P.J.K., Vahrmeijer A.L., Nortier J.W.R., Tollenaar R.A.E.M., Punt C., Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol. 2010; 21(8): 1662–7. doi:10.1093/annonc/mdp589.; Hafström L.R., Holmberg S.B., Naredi P.L., Lindnér P.G., Bengtsson A., Tidebrant G., Scherstén T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994; 3(2): 103–8. doi:10.1016/0960-7404(94)90005-1.; Rothbarth J., Pijl M.E., Vahrmeijer A.L., Hartgrink H.H., Tijl F.G., Kuppen P.J., Tollenaar R.A., van de Velde C.J. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003; 90(11): 1391–7. doi:10.1002/bjs.4308.; Huibers A., DePalo D.K., Perez M.C., Zager J.S., Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastasis. 2023. doi:10.1007/s10585-023-10234-6.; Olofsson Bagge R., Nelson A., Shafazand A., All-Eriksson C., Cahlin C., Elander N., Helgadottir H., Kiilgaard J.F., Kinhult S., Ljuslinder I., Mattsson J., Rizell M., Sternby Eilard M., Ullenhag G.J., Nilsson J.A., Ny L., Lindnér P. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol. 2023; 41(16): 3042–50. doi:10.1200/JCO.22.01705.; De Matteo R.P, Ami Shah B.S., Fong Y., Jarnagin W.R., Blumgart L.H., Brennan M.F. Results of Hepatic Resection for Sarcoma Metastatic to Liver. Ann. Surg. 2001; 234(4): 540–8. doi:10.1097/00000658-200110000-00013.; Dewald C.L.A., Becker L.S., Maschke S.K., Meine T.C., Alten T.A., Kirstein M.M., Vogel A., Wacker F.K., Meyer B.C., Hinrichs J.B. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis. 2020; 37(6): 683–92. doi:10.1007/s10585-020-10057-9.; https://www.siboncoj.ru/jour/article/view/3048
-
2Academic Journal
Authors: Ivanov, S.M., Иванов, С.М., Tkaceov, S.I., Ткачёв, С.И., Alieva, S.B., Алиева, С.Б., Medvedev, S.V., Медведев, С.В., Nazarenko, A.V., Назаренко, А.В., Glebovskaia, V.V., Глебовская, В.В., Borisova, T.N., Борисова, Т.Н., Trofimova, O.P., Трофимова, О.П., Romanov, D.S., Романов, Д.С., Abdujapparov, A.S., Абдужаппаров, А.С., Fedoseenko, D.I., Федосеенко, Д.И., Grișina, I.I., Гришина, И.И.
Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 68 (4) 196-201
Subject Terms: Стереотаксическая лучевая терапия, метастатический колоректальный рак, метастатическое поражение печени, Stereotactic radiation therapy, metastatic colorectal cancer, liver metastases
File Description: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/132211; urn:issn:18570011
Availability: https://ibn.idsi.md/vizualizare_articol/132211
-
3Academic Journal
Authors: A. P. Maltseva, V. E. Syutkin, I. Yu. Kolyshev, V. S. Rudakov, D. S. Svetlakova, Z. A. Sadykhov, Yu. D. Udalov, S. E. Voskanyan, А. П. Мальцева, В. Е. Сюткин, И. Ю. Колышев, В. С. Рудаков, Д. С. Светлакова, З. А. Садыхов, Ю. Д. Удалов, С. Э. Восканян
Source: Transplantologiya. The Russian Journal of Transplantation; Том 11, № 3 (2019); 218-233 ; Трансплантология; Том 11, № 3 (2019); 218-233 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2019-11-3
Subject Terms: гепатобластома, hepatocellular cancer, alpha-fetoprotein, immunotherapy, cholangiocarcinoma, Klatskin tumor, liver metastatic lesion, hepatoblastoma, гепатоцеллюлярный рак, альфа-фетопротеин, иммунотерапия, холангиокарцинома, опухоль Клатскина, метастатическое поражение печени
File Description: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/446/516; https://www.jtransplantologiya.ru/jour/article/view/446/524; GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. PMID: 27733281 https://doi.org/10.1016/S0140-6736(16)31012-1; Saez-Gonzalez E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, et al. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int. 2018;38(6):1022–1027. PMID: 29105320 https://doi.org/10.1111/liv.13618; Llovet JM. Liver cancer: time to evolve trial design after everolimus failure. Nat Rev Clin Oncol. 2014;11(9):506–507. PMID: 25091613 https://doi.org/10.1038/nrclinonc.2014.136; Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. PMID: 26205340 https://doi.org/10.1038/nrc3973; Kudo M. Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2018;7(1):20–27. PMID: 29662830 https://doi.org/10.1159/000486487; Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. PMID: 21374666 https://doi.org/10.1002/hep.24199; Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. PMID: 25689978 https://doi.org/10.1002/hep.27752; Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, et al. Excellent Outcomes of Liver Transplantation Following down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018;16(6):955–964. PMID: 29175528 https://doi.org/10.1016/j.cgh.2017.11.037; Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994.e3; quiz e14–5. PMID: 22750200 https://doi.org/10.1053/j.gastro.2012.05.052; Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64(6):2077–2088. PMID: 27178646 https://doi.org/10.1002/hep.28643; Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–951. PMID: 24797281 https://doi.org/10.1002/lt.23904; Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for HCC-a new MORAL to the story. Ann Surg. 2017;265(3):557-564. PMID: 27611615 https://doi.org/10.1097/SLA.0000000000001966; Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, et al. LTx- PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J Hepatobiliary Pancreat Sci. 2017;24(1):49–57. PMID: 27806426 https://doi.org/10.1002/jhbp.412; European Association for the Study of the Liver. Electronic address: easloffice@ easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. PMID: 29628281 https://doi.org/10.1016/j.jhep.2018.03.019; Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594–599. PMID: 27000463 https://doi.org/10.1634/theoncologist.2015-0446; Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463–471. PMID: 21538440 https://doi.org/10.1002/hep.24397; Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. PMID: 24681130 https://doi.org/10.1016/j.jhep.2014.01.021; Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660–667. PMID: 24410861 https://doi.org/10.1111/ajt.12591; Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338. PMID: 24769639 https://doi.org/10.1093/annonc/mdu162; Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, et al. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014;5(6):408–413. PMID: 25436118 https://doi.org/10.3978/j.issn.2078-6891.2014.072; Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016;34(3):219–226. PMID: 26503201 https://doi.org/10.1200/JCO.2015.61.3778; Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. PMID: 27622582 https://doi.org/10.1002/ cncr.30254; Dang L, White DW, Gross S, Bennett BD, Ghobrial RM, Bittinger A, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. PMID: 19935646 https://doi.org/10.1038/nature08617; Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. PMID: 29182496 https://doi.org/10.1200/JCO.2017.75.5009; Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163(4):732–738. PMID: 29336813 https://doi.org/10.1016/j.surg.2017.08.011; Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018;267(5):797–805. PMID: 29064885 https://doi.org/10.1097/SLA.0000000000002574; Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015;261(5):956–960. PMID: 24950280 https://doi.org/10.1097/SLA.0000000000000786; Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg. 2018;105(3):295–301. PMID: 29168565 https://doi.org/10.1002/bjs.10651; Grut H, Revheim ME, Line PD, Dueland S. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun. 2018;39(7):621–627. PMID: 29683930 https://doi.org/10.1097/MNM.0000000000000843; Line PD, Hagness M, Berstad AE, Foss A, Dueland S. A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept. Ann Surg. 2015;262(1):e5–9. PMID: 25692361 https://doi.org/10.1097/SLA.0000000000001165; Czaudernaa P, Haeberleb B, Hiyamac E, Rangaswamid A, Ghobrial Krailoe RM, Maibachf R, et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101. PMID: 26655560 https://doi.org/10.1016/j.ejca.2015.09.023; Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48(4):536–554. PMID: 29427028 https://doi.org/10.1007/s00247-018-4078-z; Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):3980–3999. PMID: 30254403 https://doi.org/10.3748/wjg.v24.i35.3980; https://www.jtransplantologiya.ru/jour/article/view/446
-
4Academic Journal
Authors: L. I. Moskvicheva, D. V. Sidorov, M. V. Lozhkin, L. O. Petrov, M. V. Zabelin, Л. И. Москвичева, Д. В. Сидоров, М. В. Ложкин, Л. О. Петров, М. В. Забелин
Source: Research and Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; Research'n Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; 2410-1893 ; 10.17709/2409-2231-2018-5-4
Subject Terms: стереотаксическая лучевая терапия, hepatocellular carcinoma, hepatic metastases, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound therapy, laser ablation, cryoablation, percutaneous ethanol injection, irreversible electroporation, stereotactic body radiation therapy, метастатическое поражение печени, радиочастотная абляция, микроволновая абляция, высокоинтенсивная фокусированная ультразвуковая терапия, лазерная абляция, криоабляция, химическая абляция, необратимая электропорация
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/322/272; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. Каприна А. Д., Ста-ринского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России; 2017, 250 с./Ma-lignant neoplasms in Russia in 2015 (morbidity and mortality). Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2017, р. 250 (In Russian).; Состояние онкологической помощи населению России в 2017 году. Под ред. Каприна А. Д., Старинского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018, 236 с./The state of cancer care in Russia in 2017. Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2018, р. 236 (In Russian).; Лунев С. В., Сельчук В. Ю., Чистяков С. С. Современные подходы к хирургическому лечению опухолей печени. Русский медицинский журнал. 2011;2:44-47./Lunev SV, Selchuk VYu, Chistyakov SS. Modern approaches to surgical treatment of liver tumors. Russian Medical Journal. 2011;2:44-47. (In Russian).; Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schal-ke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014 Nov 4;14:810. DOI:10.1186/1471-2407-14-810; de Haas RJ, Wicherts DA, Flores E, Ducreux M, Levi F, Paule B, et al. Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases. Ann Surg Oncol. 2010 Apr;17 (4):1010-23. DOI:10.1245/s10434-009-0887-5.; Вишневский В. А., Ефанов М. Г., Икрамов Р. З., Чжао А. В. Опухоли печени: диагностика и хирургическое лечение. Доказательная гастроэнтерология. 2013;2:38-47./Vishnevsky VA, Efanov MG, Ikramov RZ, Zhao AV. Hepatic tumours: diagnostics and surgical treatment. Russian Journal of Evidence-Based Gastroenterology (Dokazatel'naya gastroenterologiya). 2013;2:38-47. (In Russian).; Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. Gastroenterology. 2004 Nov;127 (5 Suppl 1): S35-50.; Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359 (4):378-90. DOI:10.1056/NEJMoa0708857; Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregion-al therapies in cholangiocarcinoma. Hepat Oncol. 2017 Oct;4 (4):99-109. DOI:10.2217/hep-2017-0014; Hansen PD, Cassera MA, Wolf RF. Ablative technologies for hepatocellular, cholangiocarcinoma, and metastatic colorectal cancer of the liver. Surg Oncol Clin N Am. 2015 Jan;24 (1):97-119. DOI:10.1016/j.soc.2014.09.003.; Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013 Dec;16 (4):192-200. DOI:10.1053/j.tvir.2013.08.002.; Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008 Feb;32 (2):481-90.; Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009 Mar;13 (3):486-91. DOI:10.1007/s11605-008-0727-0.; Agcaoglu O, Aliyev S, Karabulut K, El-Gazzaz G, Aucejo F, Pel-ley R, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg. 2013 Jun;37 (6):1333-9. DOI:10.1007/s00268-013-1981-1; Razafindratsira Т, Isamber М, Evrard S. Complications of intraoperative radiofrequency ablation of liver metastases. HPB. 2011;13:15-23. https://doi.org/10.1111/j.1477-2574.2010.00243.x; Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008 Oct;15 (10):2757-64. DOI:10.1245/s10434-008-0043-7; Nielsen K, van Tilborg AA, Meijerink MR, Macintosh MO, Zon-derhuis BM, de Lange ES, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013 Jun;37 (6):1340-7. DOI:10.1007/s00268-013-1997-6.; Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, et al. Long term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011 Jun;84 (1002):556-65. DOI:10.1259/bjr/78268814.; Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011 Jul;81 (1):25-34. DOI:10.4174/jkss.2011.81.1.25; Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012 Oct;23 (10):2619-26. DOI:10.1093/annonc/mds053; Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017 Sep 1;109 (9). DOI:10.1093/jnci/djx015.; Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013 Jan;58 (1):89-97. DOI:10.1016/j.jhep.2012.09.020; Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005 Sep;11 (9):1117-26. DOI:10.1002/lt.20469; Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006 May;186 (5 Suppl): S296-305. DOI:10.2214/AJR.04.1927; Sun Y, Cheng Z, Dong L, Zhang G, Wang Y, Liang P. Comparison of temperature curve and ablation zone between 915-and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol. 2012 Mar;81 (3):553-7. DOI:10.1016/j.ejrad.2011.02.013.; Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J Vasc Interv Radiol. 2018 Feb;29 (2):268-275.e1. DOI:10.1016/j.jvir.2017.08.021.; Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017 Feb 9;8 (31):51792-51799. DOI:10.18632/oncotarget.15244.; Zhou F, Yu X, Liang P, Han Z, Cheng Z, Yu J, et al. Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? — Lessons from 10 years' experience. Oncotarget. 2017 Jun 28;8 (59):100791-100800. DOI:10.18632/oncotarget.18764.; Livraghi T, Meloni F, Solbiati L, Zanus G, Noto A, Goleffi O, et al. Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol. 2012 Aug;35 (4):868—74. DOI:10.1007/s00270-011-0241-8; Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000 Jul 15;89 (2):276-84.; Alexander ES, Wolf FJ, Machan JT, Charpentier KP, Beland MD, Iannuccilli JD, et al. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. Eur J Radiol. 2015 Jun;84 (6):1083-90. DOI:10.1016/j. ejrad.2015.02.027; Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol. 2015 Aug;26 (8):1139-1146.e2. DOI:10.1016/j.jvir.2015.04.004.; Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015 Mar 15;111 (4):410-3. DOI:10.1002/jso.23849.; Sun AX, Cheng ZL, Wu PP, Sheng YH, Qu XJ, Lu W, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World J Gastroenterol. 2015 Mar 14;21 (10):2997-3004. DOI:10.3748/wjg.v21.i10.2997.; Ginsburg M, Zivin SP, Wroblewski K, Doshi T, Vasnani RJ, Van Ha TG. Comparison of Combination Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboli-zation with Radiofrequency Ablation versus Microwave Ablation. J Vasc Interv Radiol. 2015 Mar;26 (3):330-41. DOI:10.1016/j.jvir.2014.10.047.; van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Futter-er JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017 Feb;66 (2):247-258. DOI:10.1007/s00262-016-1891-9.; Dupre A, Melodelima D, Perol D, Chen Y, Vincenot J, Chapelon JY, Rivoire M. First Clinical Experience of Intra-Operative High Intensity Focused Ultrasound in Patients with Colorectal Liver Metastases: A Phase I-IIa Study. PLoS One. 2015 Feb 26;10 (2): e0118212. DOI:10.1371/journal.pone.0118212.; Mearini L. High intensity focused ultrasound, liver disease and bridging therapy. World J Gastroenterol. 2013 Nov 21;19 (43):7494-9. DOI:10.3748/wjg.v19.i43.7494.; Li JJ, Gu MF, Luo GY, Liu LZ, Zhang R, Xu GL. Complications of high intensity focused ultrasound for patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2009 Jun;8 (3):217-24. DOI:10.1177/153303460900800306; Xu G, Luo G, He L, Li J, Shan H, Zhang R, Li Y, et al. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. Ultrasound Med Biol. 2011 Dec;37 (12):1993-9. DOI:10.1016/j.ultrasmedbio.2011.08.011; Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, Chu F, et al. High-intensity focused ultrasound for hepatocellular carcinoma. Ann Surg. 2011 May;253 (5):981-7. DOI:10.1097/SLA.0b013e3182128a8b.; Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford). 2013 Aug;15 (8):567-73. DOI:10.1111/hpb.12025.; Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Advanced hepatocellular carcinoma: treatment with high intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005 May;235 (2):659-67. DOI:10.1148/ra-diol.2352030916; Vogl TJ, Farshid P, Naguib NN, Darvishi A, Bazrafshan B, Mbal-isike E, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014 Jul;119 (7):451-61. DOI:10.1007/s11547-014-0415-y; Di Costanzo GG, D'Adamo G, Tortora R, Zanfardino F, Mat-tera S, Francica G, Pacella CM. A novel needle guide system to perform percutaneous laser ablation of liver tumors using the multifiber technique. Acta Radiol. 2013 Oct;54 (8):876-81. DOI:10.1177/0284185113489825.; Tombesi P, Di Vece F, Sartori S. Laser ablation for hepatic metastases from neuroendocrine tumors. AJR Am J Roentgenol. 2015 Jun;204 (6): W732. DOI:10.2214/AJR.14.14242.; Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7 (4):477-489. DOI:10.4292/wjgpt.v7.i4.477; Yu H, Burke CT. Comparison of Percutaneous Ablation Technologies in the Treatment of Malignant Liver Tumors. Semin Intervent Radiol. 2014 Jun;31 (2):129-37. DOI:10.1055/s-0034-1373788.; Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012 Oct;46 (9):796-801. DOI:10.1097/MCG.0b013e3182641806; Sartori S, Di Vece F, Ermili F, Tombesi P. Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave? World J Radiol. 2017 Mar 28;9 (3):91-96. doi:10.4329/wjr.v9.i3.91.; Di Costanzo GG, Tortora R, D'Adamo G, De Luca M, Lampasi F, Addario L, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015 Mar;30 (3):559-65. DOI:10.1111/jgh.12791.; Qu J, Gao X, Chen Y, Zhou L, Wu Y, Feng Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012 Nov;19 (6):674-84. DOI:10.1007/s00534-011-0490-6.; Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to LongTerm Outcomes. AJR Am J Roentgenol. 2017 Dec;209 (6):1381-1389. DOI:10.2214/AJR.16.17582; Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010 Jul;22 (4):364-73. DOI:10.1097/CCO.0b013e32833a6c8a; Wu B, Xiao YY, Zhang X, Zhang AL, Li HJ, Gao DF. Magnetic resonance imaging-guided percutaneous cryoablation of hepatocellular carcinoma in special regions. Hepatobiliary Pancreat Dis Int. 2010 Aug;9 (4):384-92.; Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, et al. Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PLoS One. 2015 Apr 7;10 (4): e0123065. DOI:10.1371/journal.pone.0123065; Xu K-C, Niu L-Z, He W-B, Hu Y-Z, Zuo J-S. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol. 2008 Mar 7;14 (9):1430-6.; Shimizu T, Sakuhara Y, Abo D, Hasegawa Y, Kodama Y, Endo H, et al. Outcome of MR-guided percutaneous cryoabla-tion for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16:816-823. https://doi.org/10.1007/s00534-009-0124-4; Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porche-ron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007 Jun;33 (5):590-6. DOI:10.1016/j.ejso.2007.01.003; Xu K-C, Niu L-Z, Zhou Q, Hu Y-Z, Guo D-H, Liu Z-P, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009 Aug 7;15 (29):3664-9.; McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol. 2010 Sep;27 (3):255-60. DOI:10.1055/s-0030-1261783.; Mahnken AH, Bruners P, Gunther RW. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis. 2009;27 (2):148-56. DOI:10.1159/000218347.; Kwon JH. Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation? Gut Liver. 2010 Sep;4 Suppl 1: S105-12. DOI:10.5009/gnl.2010.4.S1.S105; Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005 May;31 (4):331-47. DOI:10.1016/j.ejso.2004.10.011; Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farel-la N, Mariniello A, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011 Jun;31 (6):2291-5.; Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012 Mar 14;18 (10):1003-8. DOI:10.3748/wjg. v18.i10.1003; Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshika-wa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year ob-servation. J Hepatol. 2005 Sep;43 (3):458-64. DOI:10.1016/j.jhep.2005.03.033; Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006 Jun 21;12 (23):3707-15.; Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005 Jul;92 (7):856-8. DOI:10.1002/bjs.4986; Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003 Feb;237 (2):171-9. DOI:10.1097/01.SLA.0000048443.71734.BF; Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005 Aug;54 (8):1151-6. DOI:10.1136/gut.2004.045203; Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007 Aug;244 (2):599-607. DOI:10.1148/radi-ol.2442060826; Branco F, Bru C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol. 2009 Jul-Sep;8 (3):220-7.; Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017 Mar 13;4:49-58. DOI:10.2147/JHC.S129063.; Qasrawi R, Silve L, Burdio F, Abdeen Z, Ivorra A. Anatomically Realistic Simulations of Liver Ablation by Irreversible Electroporation: Impact of Blood Vessels on Ablation Volumes and Undertreatment. Technol Cancer Res Treat. 2017 Jan 1:1533034616687477. DOI:10.1177/1533034616687477.; Ruarus AH, Vroomen LGPH, Puijk RS, Scheffer HJ, Zonderhu-is BM, Kazemier G, et al. Irreversible Electroporation in Hepa-topancreaticobiliary Tumours. Can Assoc Radiol J. 2018 Feb;69 (1):38-50. DOI:10.1016/j.carj.2017.10.005.; Dollinger M, Muller-Wille R, Zeman F, Haimerl M, Niessen C, Beyer LP, et al. Irreversible electroporation of malignant hepatic tumors — alterations in venous structures at subacute follow-up and evolution at mid-term follow-up. PLoS One. 2015 Aug 13;10 (8): e0135773. DOI:10.1371/journal.pone.0135773.; Dollinger M, Zeman F, Niessen C, Lang SA, Beyer LP, Muller M, et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol. 2016 Jan;27 (1):96-103. DOI:10.1016/j.jvir.2015.10.002; Niessen C, Beyer LP, Pregler B, Dollinger M, Trabold B, Schlit-t=HJ, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: a prospective safety and midterm efficacy study in 34 patients. J Vasc Interv Radiol. 2016 Apr;27 (4):480-6. DOI:10.1016/j.jvir.2015.12.025; Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016 Jul;18 (7):593-9. DOI:10.1016/j.hpb.2016.03.609; Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016 Nov;6 (1):34-43. DOI:10.1159/000449346; Lyu T, Wang X, Su Z, Shangguan J, Sun C, Figini M, et al. Irreversible electroporation in primary and metastatic hepatic malignancies. A review. Medicine (Baltimore). 2017 Apr;96 (17): e6386. DOI:10.1097/MD.0000000000006386.; Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous Irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017 Mar 7;7:43687. DOI:10.1038/srep43687; Scorseffi M, Comito T, Tozzi A, Navarria P, Fogliata A, Cleri-ci E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015 Mar;141 (3):543—53. doi:10.1007/s00432-014-1833-x; Mutsaers A, Greenspoon J, Walker-Dilks C, Swaminath A. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol. 2017 Jun 29;12 (1):110. DOI:10.1186/s13014-017-0818-8.; Liu X, Song Y, Liang P, Su T, Zhang H, Zhao X, et al. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients. Onco Targets Ther. 2017 Nov 6;10:5289-5295. DOI:10.2147/OTT.S142025.; Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017 Oct 19;12 (1):163. DOI:10.1186/s13014-017-0899-4; Деньгина Н. В., Мозерова Е. Я. Стереотаксическая лучевая терапия и локальная гипертермия в лечении опухолей различных локализаций. Практическая онкология. 2015;16 (4):162-173./Dengina NV, Mozerova EYa. Stereotactic body radiotherapy and local hyperthermia in the treatment of various malignant tumors. Practical Oncology. 2015;16 (4):162-173 (In Russian).; Kim TH, Park J-W, Kim BH, Kim DY, Moon SH, Kim SS, et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017 Dec 19;9 (3):4034-4043. DOI:10.18632/oncotarget.23428.; Mendez Romero A, Keskin-Cambay F, van Os RM, Nuyt-tens JJ, Heijmen BJM, IJzermans JNM, Verhoef C. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017 Mar-Apr;22 (2):126-131. DOI:10.1016/j.rpor.2016.10.003; Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundar-araman S, D'Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis — clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018 Feb 13;13 (1):26. DOI:10.1186/s13014-018-0969-2.; https://www.rpmj.ru/rpmj/article/view/322
-
5Academic Journal
Authors: A. S. Zagainov, A. V. Shelekhov, V. V. Dvornichenko, R. I. Rasulov, R. A. Zubkov, А. С. Загайнов, А. В. Шелехов, В. В. Дворниченко, Р. И. Расулов, Р. А. Зубков
Source: Siberian journal of oncology; Том 16, № 1 (2017); 66-70 ; Сибирский онкологический журнал; Том 16, № 1 (2017); 66-70 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-16-1
Subject Terms: резекция печени, metastatic liver disease, chemoembolization, hepatic resection, метастатическое поражение печени, химиоэмболизация
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/493/413; Venderbosch S., de Wilt J.H., Teerenstra S., Loosveld O.J., van Bochove A., Sinnige H.A., Creemers G.J., Tesselaar M.E., Mol L., Punt C.J., Koopman M. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective anaysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011 Nov; 18 (12): 3252 60. doi:10.1245/s10434-011-1951-5.; Chua T.C., Saxena A., Liauw W., Kokandi A., Morris D.L. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010 Feb; 17 (2): 492 501. doi:10.1245/s10434-009-0781-1.; Cui Y., Li H., Wu Q., Zhang T., Kong D., Song T., Ru T., Chen P., Li Q. Treatment of colorectal cancer with unresectable synchronous liveronly metastases with combined therapeutic modalities. J Gastrointest Surg. 2011 Feb; 15 (2): 285 93. doi:10.1007/s11605-010-1357-x.; Capussotti L., Ferrero A., Vigano L., Ribero D., Lo Tesoriere R., Polastri R. Major Liver Resections Synchronous with Colorectal Surgery. Annals of Surgical Oncology. 2007; 14 (1): 195–201. doi:10.1245/ s10434-006-9055-3.; Афанасьев С.Г., Добродеев А.Ю. Циторедуктивные операции (Нужно ли удалять первичную опухоль? Где предел разумной циторедукции? Практическая онкология. 2014; 15 (2): 93–100.; Karoui M., Vigano L., Goyer P., Ferrero A., Luciani A., Aglietta M., Delbaldo C., Cirillo S., Capussotti L., Cherqui D. Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. Br J Surg. 2010 Sep; 97 (9): 1354 62. doi:10.1002/bjs.7128.; Gonsalves C.F., Brown D.B. Chemoembolization of hepatic malignancy. Abdom Imaging. 2009 Sep-Oct; 34 (5): 557 65. doi:10.1007/ s00261-008-9446-y.; Афанасьев С.Г., Тузиков С.А. Нерезектабельные опухоли печени (обзор литературы). Сибирский онкологический журнал. 2006; 1: 49–54.; https://www.siboncoj.ru/jour/article/view/493
-
6Academic Journal
Authors: A. S. Zagainov, R. I. Rasulov, A. V. Shelekhov, R. A. Zubkov, V. V. Dvornichenko, А. С. Загайнов, Р. И. Расулов, А. В. Шелехов, Р. А. Зубков, В. В. Дворниченко
Source: Acta Biomedica Scientifica; Том 2, № 3 (2017); 14-17 ; 2587-9596 ; 2541-9420
Subject Terms: резекция печени, metastatic liver disease, chemoembolization, hepatic resection, метастатическое поражение печени, химиоэмболизация
File Description: application/pdf
Relation: https://www.actabiomedica.ru/jour/article/view/382/383; Таразов П.Г., Гранов Д.А., Поликарпов А.А., Полысалов В.Н. Комбинированная химиоэмболизация печеночной артерии и воротной вены при метастазах колоректального рака в печень // Вопросы онкологии. - 2002. - Т. 48, № 1. - С. 83-87; Aslam M.I., Kelkar A., Sharpe D., Jameson J.S. / (2010). Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int. J. Surg., 8, 305-313.; Birth M., Hildebrand P., Dahmen G., Ziegler A., Broring D.C., Hillert C., Bruch H.P. (2004). Present state of radio frequency ablation of liver tumors in Germany. Chirurg, 75, 417-423.; Brenner H., Kloor M., Pox C.P. (2014). Colorectal cancer. Lancet, 383 (9927), 1490-1502. doi:10.1016/S0140-6736(13)61649-9.; Chua T.C., Saxena A., Liauw W., Kokandi A., Morris D.L. (2010). Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann. Surg. Oncol., 17, 492-501.; Figueras J., Torras J., Valls C., Llado L., Ramos E., Marti-Rague J., Serrano T., Fabregat J. (2007). Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis. Colon. Rectum, 50, 478-488.; Gonsalves C.F., Brown D.B. (2009). Chemo-embolization of hepatic malignancy. Abdom. Imaging, 34, 557-565.; Haugeberg G., Strohmeyer Т., Lierse W., Bocker W. (1988). The vascularization of liver metastases. Histological investigation of gelatine-injected liver specimens with special regard to the vascularization of micrometastases. J. Cancer. Res. Clin. Oncol., 14 (4), 415419.; Martin R.C., Joshi J.K., Robbins K., Tomalty D., Bosnjakovik P., Derner M., Padr R., Rocek M., Scupchenko A., Tatum C. (2011). Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI), in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multiinstitutional study. Ann. Surg. Oncol., 18 (1), 192-198.; Mulier S., Mulier P., Ni Y., Miao Y., Dupas B., Marchal G., De Wever I., Michel L. (2002). Complications of radiofrequence coagulation of liver tumours. Br. J. Surg., 176, 3-16.; Solbiati L., Ahmed M., Cova L., Ierace T., Brioschi M., Goldberg S.N. (2012). Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology, 265 (3), 958-968.; Stelzner S., Hellmich G., Koch R., Ludwig K. (2005). Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J. Surg. Oncol., 89, 211-217.; https://www.actabiomedica.ru/jour/article/view/382
-
7Academic Journal
-
8Academic Journal
File Description: text/html
-
9Academic Journal
Authors: БЕБУРИШВИЛИ А.Г., ЗЮБИНА Е.Н., СПИРИДОНОВ ЕВГЕНИЙ ГЕННАДИЕВИЧ, ЯЦЫШЕН В.В., МОЗГОВОЙ П.В., ЕВСЮКОВ О.Ю., АЛЕЙНИКОВА Е.С.
File Description: text/html
-
10Academic Journal
Authors: ТКАЧЁВ С.И., МЕДВЕДЕВ С.В., РОМАНОВ Д.С., БУЛЫЧКИН П. В, ЮРЬЕВА Т.В., ГУТНИК Р.А., ЯЖГУНОВИЧ И.П., БЕРДНИК А.В., БЫКОВА Ю.Б.
File Description: text/html
-
11Academic Journal
Authors: S. S. Bagnenko, G. Ye. Trufanov
Source: Бюллетень сибирской медицины, Vol 11, Iss 1, Pp 171-178 (2012)
Subject Terms: печень, магнитно-резонансная томография, количественный анализ, динамическое контрастное усиление, многофазное сканирование, очаговые образования печени, гепатоцеллюлярный рак, метастатическое поражение печени, холангиоцеллюлярный рак, гемангиома печени, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/426; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/13bb6508c65f413b8e58f65dad0a5ff9
-
12Academic Journal
Authors: Багненко, Сергей, Труфанов, Г.
Subject Terms: ПЕЧЕНЬ, МАГНИТНО-РЕЗОНАНСНАЯ ТОМОГРАФИЯ, КОЛИЧЕСТВЕННЫЙ АНАЛИЗ, ДИНАМИЧЕСКОЕ КОНТРАСТНОЕ УСИЛЕНИЕ, МНОГОФАЗНОЕ СКАНИРОВАНИЕ, ОЧАГОВЫЕ ОБРАЗОВАНИЯ ПЕЧЕНИ, ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК, МЕТАСТАТИЧЕСКОЕ ПОРАЖЕНИЕ ПЕЧЕНИ, ХОЛАНГИОЦЕЛЛЮЛЯРНЫЙ РАК, ГЕМАНГИОМА ПЕЧЕНИ, КИСТА ПЕЧЕНИ, АБСЦЕСС ПЕЧЕНИ, АДЕНОМА ПЕЧЕНИ, ОЧАГОВАЯ УЗЛОВАЯ ГИПЕРПЛАЗИЯ ПЕЧЕНИ
File Description: text/html
-
13Academic Journal
Source: Бюллетень медицинских интернет-конференций.
File Description: text/html
-
14Academic Journal
Source: Злокачественные опухоли.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, МЕТАСТАТИЧЕСКОЕ ПОРАЖЕНИЕ ПЕЧЕНИ,СТЕРЕОТАКСИЧЕСКАЯ РАДИОХИРУРГИЯ,ЛОКАЛЬНЫЙ КОНТРОЛЬ
File Description: text/html
-
15Academic Journal
Source: Пермский медицинский журнал.
Subject Terms: МЕТАСТАТИЧЕСКОЕ ПОРАЖЕНИЕ ПЕЧЕНИ,METASTATIC HEPATIC LESION,РЕЗЕКЦИЯ ПЕЧЕНИ,HEPATIC RESECTION,ОБЩАЯ ПРОДОЛЖИТЕЛЬНОСТЬ ЖИЗНИ,GENERAL DURATION OF LIFE, 3. Good health
File Description: text/html
-
16Academic Journal
Source: Вестник Волгоградского государственного медицинского университета.
File Description: text/html
-
17Academic Journal
Source: Бюллетень сибирской медицины.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ПЕЧЕНЬ, МАГНИТНО-РЕЗОНАНСНАЯ ТОМОГРАФИЯ, КОЛИЧЕСТВЕННЫЙ АНАЛИЗ, ДИНАМИЧЕСКОЕ КОНТРАСТНОЕ УСИЛЕНИЕ, МНОГОФАЗНОЕ СКАНИРОВАНИЕ, ОЧАГОВЫЕ ОБРАЗОВАНИЯ ПЕЧЕНИ, ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК, МЕТАСТАТИЧЕСКОЕ ПОРАЖЕНИЕ ПЕЧЕНИ, ХОЛАНГИОЦЕЛЛЮЛЯРНЫЙ РАК, ГЕМАНГИОМА ПЕЧЕНИ, КИСТА ПЕЧЕНИ, АБСЦЕСС ПЕЧЕНИ, АДЕНОМА ПЕЧЕНИ, ОЧАГОВАЯ УЗЛОВАЯ ГИПЕРПЛАЗИЯ ПЕЧЕНИ
File Description: text/html
-
18
Authors: Камгуя Феукви Херве, Kamgua Feukvi Herve
Contributors: Аржаник Марина Борисовна, Arzanik Marina Borisovna, Гончарова Анастасия Борисовна, Goncarova Anastasia Borisovna
Subject Terms: свёрточные нейронные сети, ультразвуковое исследование, метастатическое поражение печени, видеозаписи, псевдоколоризация, сonvolutional neural network, ultrasound examination, metastatic liver damage, video recordings, saliency maps
Relation: 093241; http://hdl.handle.net/11701/47885
Availability: http://hdl.handle.net/11701/47885
-
19Academic Journal
Authors: Добровольский, Н. А., Биленко, А. А., Пурин, А. Г., Воронов, И. А., Косаковский, Д. И., Машуков, А. А., Макашовский, В. Е., Рациборский, Д. В.
Subject Terms: колоректальный рак, метастатическое поражение печени
File Description: application/pdf
Availability: https://repo.odmu.edu.ua:443/xmlui/handle/123456789/7781
